Publication:
Improvement of vascular function by chronic administration of a cyclo-oxygenase inhibitor in cholesterol-fed rabbits

dc.contributor.authorSrisawat S.
dc.contributor.authorPhivthong-Ngam L.
dc.contributor.authorUnchern S.
dc.contributor.authorChantharaksri U.
dc.contributor.authorGovitrapong P.
dc.contributor.authorSanvarinda Y.
dc.date.accessioned2021-04-05T04:32:54Z
dc.date.available2021-04-05T04:32:54Z
dc.date.issued2003
dc.date.issuedBE2546
dc.description.abstract1. Atherosclerotic cardio- and cerebrovascular disease is a leading cause of mortality in Western countries. Aspirin-like drugs are widely used to prevent and treat these occlusive cardio- and cerebrovascular diseases. The beneficial effects of these drugs have been largely attributed to inhibition of platelet cyclo-oxygenase activity and thromboxane (TX) A2 production. We investigated the effect of an aspirin-like drug, namely indomethacin, on endothelial function, plaque and platelet aggregation and the formation of vasoactive substances during the development of atherosclerosis in cholesterol-fed rabbits. 2. Rabbits were fed 1% cholesterol (n = 8), 1% cholesterol plus 25 mg/day indomethacin (n = 8) or normal rabbit chow (control group; n = 8) for 12 weeks. Urinary excretion rates of 2,3-dinor-TXB2, 6-keto-prostaglandin (PG) F1α, 8-iso-PGF2α, and nitrate were analysed at the beginning of dietary intervention and at 4 weekly intervals thereafter. At the end of the study period, platelet aggregation, aortic plaque formation and endothelium-dependent and -independent vascular functions of isolated aortic rings ex vivo were assessed. 3. Compared with control, in the cholesterol-fed group, urinary 2,3-dinor-TXB2, 6-keto-PGF1α and 8-iso-PGF2α excretion and platelet aggregation were significantly increased (P < 0.05), but urinary excretion of nitrate was decreased (P < 0.05). Treatment with indomethacin significantly reduced platelet aggregation, urinary 2,3-dinor-TXB2, 6-keto-PGF1α, and 8-iso-PGF2α excretion (P < 0.05 vs the cholesterol-fed group) and attenuated the reduction in urinary nitrate excretion. 4. Cholesterol feeding progressively increased aortic intimal thickening and impaired endothelium-dependent vasodilator function (P < 0.05 vs control), whereas indomethacin partially prevented aortic plaque formation and restored endothelium-dependent vasodilation (P < 0.05 vs the cholesterol-fed group). 5. The present study demonstrates that indomethacin reduces the progression of atherosclerotic lesions and improves endothelium-mediated vascular responses ex vivo in cholesterol-fed rabbits. The beneficial effects of indomethacin may be due to its ability to prevent the elevation of platelet aggregation, TXA2 (measured as urinary 2,3-dinor-TXB2 excretion) and 8-iso-PGF2α, formation and to retard the decrease in endogenous nitric oxide synthesis (assessed as urinary excretion of nitrate). Despite indomethacin treatment leading to the suppression of prostacyclin biosynthesis (assessed as urinary 6-keto-PGF1α excretion), according to our data, indomethacin appears to preserve endothelial function.
dc.format.mimetypeapplication/pdf
dc.identifier.citationClinical and Experimental Pharmacology and Physiology. Vol 30, (2003), p.405-412
dc.identifier.doi10.1046/j.1440-1681.2003.03850.x
dc.identifier.issn3051870
dc.identifier.other2-s2.0-0038809114
dc.identifier.urihttps://hdl.handle.net/20.500.14740/6586
dc.rights.holderมหาวิทยาลัยศรีนครินทรวิโรฒ
dc.subject.other2,3 dinorthromboxane B2
dc.subject.other6 oxoprostaglandin F1 alpha
dc.subject.other8 isoprostaglandin F2 alpha
dc.subject.otherAcetylsalicylic acid
dc.subject.otherCholesterol
dc.subject.otherIndometacin
dc.subject.otherNitrate
dc.subject.otherNitric oxide
dc.subject.otherProstacyclin
dc.subject.otherProstaglandin synthase inhibitor
dc.subject.otherThromboxane A2
dc.subject.otherAnimal cell
dc.subject.otherAnimal model
dc.subject.otherAnimal tissue
dc.subject.otherArtery intima proliferation
dc.subject.otherArticle
dc.subject.otherAtherosclerosis
dc.subject.otherAtherosclerotic plaque
dc.subject.otherBlood vessel function
dc.subject.otherCerebrovascular disease
dc.subject.otherControlled study
dc.subject.otherCoronary artery atherosclerosis
dc.subject.otherDiet
dc.subject.otherEndothelium
dc.subject.otherMale
dc.subject.otherMortality
dc.subject.otherNonhuman
dc.subject.otherRabbit
dc.subject.otherThrombocyte aggregation
dc.subject.otherUrinary excretion
dc.subject.otherAnimals
dc.subject.otherAorta, Thoracic
dc.subject.otherArteriosclerosis
dc.subject.otherCholesterol, Dietary
dc.subject.otherCyclooxygenase Inhibitors
dc.subject.otherEndothelium, Vascular
dc.subject.otherMale
dc.subject.otherRabbits
dc.subject.otherVasodilation
dc.titleImprovement of vascular function by chronic administration of a cyclo-oxygenase inhibitor in cholesterol-fed rabbits
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-0038809114&doi=10.1046%2fj.1440-1681.2003.03850.x&partnerID=40&md5=614cdd7a0c2f6603f71cc13dfb8bbbf5

Files